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Abstract
Background: Tuberculosis is a major health concern in prisons, particularly where HIV prevalence is high. Our objective was
to determine the undiagnosed pulmonary tuberculosis (‘‘undiagnosed tuberculosis’’) prevalence in a representative sample
of prisoners in a South African prison. In addition we investigated risk factors for undiagnosed tuberculosis, to explore if
screening strategies could be targeted to high risk groups, and, the performance of screening tools for tuberculosis.
Methods and Findings: In this cross-sectional survey, male prisoners were screened for tuberculosis using symptoms, chest
radiograph (CXR) and two spot sputum specimens for microscopy and culture. Anonymised HIV antibody testing was
performed on urine specimens. The sensitivity, specificity and predictive values of symptoms and investigations were
calculated, using Mycobacterium tuberculosis isolated on sputum culture as the gold standard. From September 2009 to
October 2010, 1046 male prisoners were offered enrolment to the study. A total of 981 (93.8%) consented (median age was
32 years; interquartile range [IQR] 27–37 years) and were screened for tuberculosis. Among 968 not taking tuberculosis
treatment and with sputum culture results, 34 (3.5%; 95% confidence interval [CI] 2.4–4.9%) were culture positive for
Mycobacterium tuberculosis. HIV prevalence was 25.3% (242/957; 95% CI 22.6–28.2%). Positive HIV status (adjusted odds
ratio [aOR] 2.0; 95% CI 1.0–4.2) and being an ex-smoker (aOR 2.6; 95% CI 1.2–5.9) were independently associated with
undiagnosed tuberculosis. Compared to the gold standard of positive sputum culture, cough of any duration had a
sensitivity of 35.3% and specificity of 79.6%. CXR was the most sensitive single screening modality (sensitivity 70.6%,
specificity 92.2%). Adding CXR to cough of any duration gave a tool with sensitivity of 79.4% and specificity of 73.8%.
Conclusions: Undiagnosed tuberculosis and HIV prevalence was high in this prison, justifying routine screening for
tuberculosis at entry into the prison, and intensified case finding among existing prisoners.
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Introduction
Prisoners worldwide are at a disproportionately high risk of
tuberculosis [1,2] as well as HIV infection [3], a potent risk factor
for tuberculosis. Prisoners may originate from deprived commu-
nities with high rates of tuberculosis. Within prisons, overcrowd-
ing, poor ventilation and nutrition, limited health services and a
mobile population can contribute to ongoing disease transmission
[4,5]. Studies from Sub-Saharan African prisons suggest that 0.7%
to 5.8% prisoners have undiagnosed active tuberculosis [4,6–12],
with multi-drug resistant (MDR) tuberculosis in 9.5% of isolates in
one survey from Zambia [9].
In South Africa, the estimated adult prevalence of HIV
infection was 18% in 2009 [13] and tuberculosis incidence was
estimated at 981/100,000 in 2010 [14]; with an HIV prevalence of
60% among tuberculosis patients [14]. South Africa has the third
highest incarceration rate in Africa with 316 prisoners per 100,000
population in 2011 [15]. However, there are no representative
data regarding the prevalence of tuberculosis [16] or HIV among
South Africa’s prisoners [17–19].
When a high prevalence of tuberculosis is anticipated, screening
to identifying those requiring further investigation is important. A
screening strategy should be easy to implement, and the tool/s
used should have high sensitivity. This is usually followed with a
diagnostic test of high specificity to identify patients with
tuberculosis. International guidelines concerning tuberculosis
control in prisons [5,20,21] recommend systematic screening of
new entrants using a standardised symptom screen and if resources
permit, especially in high tuberculosis prevalence settings, chest
radiography to identify those requiring further investigation.
Additional strategies advocated include sputum microscopy at
entry [21] in high burden settings and periodic screening of all
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prisoners [5,20–22]. The suggested screening symptoms differ
between guidelines. A recent systematic review [2] indicated that
only 3/52 countries included, all from low and middle income
settings, used the World Health Organization (WHO) scoring
system recommended for prisons [20], which has reported
sensitivities ranging from 58% to 64% for bacteriologically
confirmed tuberculosis [23,24]. New WHO guidelines for
intensified case finding (ICF) among people with HIV recommend
screening with any one of current cough, fever, weight loss or night
sweats [25], but data on the performance of this tool within prisons
is lacking. Studies from prisons investigating screening tools to
identify active tuberculosis are restricted, as not all comparator
screening methods were used on all participants regardless of
symptoms [23,24,26,27]. Determining the sensitivity and specific-
ity of individual tools, including symptoms in this setting, has
therefore been limited. There is an urgent need to evaluate how
best to screen prisoners for active tuberculosis.
We conducted a cross-sectional survey of prisoners in South
Africa’s largest prison, in Johannesburg, housing up to 13,000
prisoners. At the time of the study, new entrants were screened for
tuberculosis by enquiring on possible symptoms, which was not
performed in a standardised manner; periodic screening and chest
radiography were not routine. Prisoners with drug-resistant
tuberculosis were segregated, but those who were sputum smear-
positive for acid fast bacilli were not. HIV counselling and testing
(HCT) and antiretroviral therapy (ART) have been available since
2007. The aim of the study was to determine the prevalence of
active undiagnosed pulmonary tuberculosis (henceforth called
undiagnosed tuberculosis) in the prison. In addition risk factors for
undiagnosed tuberculosis were explored in order to investigate if
screening strategies could be targeted to high risk groups; and the
performance of symptom combinations and standard investiga-
tions in the diagnosis of tuberculosis was evaluated in this prison.
Methods
Ethics Statement
The study was approved by the Research Ethics Committees of
the Department of Correctional Services, South Africa, the
University of KwaZulu-Natal, South Africa and the London
School of Hygiene & Tropical Medicine, UK; and the Centers for
Disease Control (CDC) Institutional Review Board. The study was
also approved by the Office for Human Research Protections
(OHRP), USA.
All participants gave voluntary written informed consent, or
verbal consent which was witnessed if unable to write. Study
procedures were explained to the participants by trained research
nurses, and participant information sheets were provided for
participants to read. Participant information sheets were available
in the most common local languages. Comprehension was
ascertained prior to obtaining consent by asking participants to
repeat back in their own words, their understanding of the study
and procedures if they took part. If verbal consent was being
provided, witnesses who were neither prison nor study staff were
chosen by the participants; the participant’s thumbprint and the
witness’s signature were used on the consent form. Participants
with diminished capacity were not recruited to the study. Consent
was specifically sought to undertake anonymised urine HIV testing
from each study participant. All research ethics committees, review
boards and the OHRP were aware and approved HIV testing
procedures.
Consent and participation in the study was voluntary. Partic-
ipants were able to refuse to take part, with no consequences to
their healthcare or any other services as a result of this.
Study Design and Population
The study site was the prison block housing sentenced male
prisoners. Enrolment to the study took place between September
2009 and October 2010. Two groups of prisoners were
approached to take part. The first was a simple random sample
of prisoners who had been incarcerated for at least six months
(‘‘currently incarcerated’’) at the start of the study. The second
group were a consecutive sample of ‘‘newly-sentenced’’ prisoners
who were entering the study site after having been sentenced in
court. All those with an expected stay less than three months were
excluded, as follow-up of medical records could not be assured.
Study Procedures
All participants underwent a standardised symptom question-
naire, chest radiography (assessed by two readers using a
standardised tool), and provided two spot sputum specimens for
smear and mycobacterial culture. Urine for anonymised HIV
testing was collected from those consenting; which was used only
for study purposes. Results of anonymised urine HIV testing, was
not given to study participants. For those wanting to know their
HIV status, HCT, with linkage to appropriate care as necessary,
was offered.
Tuberculosis suspects, defined as participants with clinical
(respiratory symptoms, fever, night sweats, loss of appetite,
lethargy, unintentional weight loss, temperature $38oC) and/or
radiological features of tuberculosis, and/or positive sputum smear
(any grade) or culture, were referred to the prison medical services
for further management. All prisoners referred were managed
according to the South African National Tuberculosis Control
Programme Practical Guidelines [28]. They were reviewed one
month later with repeat symptom screen, chest radiography, and
two further sputum samples for smear and culture. Prison medical
records of all prisoners enrolled to the study, without a diagnosis of
tuberculosis during the study, were reviewed at three months post-
enrolment to ascertain any tuberculosis diagnoses missed.
Laboratory Methods
Sputum specimens underwent fluorochrome microscopy and
liquid culture, at the National Health Laboratory Services of
South Africa. Ten percent of all microscopy slides were double
read, for quality control purposes. Positive cultures underwent
speciation using GenoTypeH Mycobacterium CM (Hain Life-
science, Nehren, Germany) and drug susceptibility testing for
isoniazid and rifampicin.
Anonymised urine samples were tested for HIV antibodies using
the MAXIM HIV-1 urine EIA (Maxim Biomedical Inc, MD,
USA). The urine EIA has a reported sensitivity of 99% and
specificity of 90% among high HIV risk populations [29].
Definitions
Tuberculosis was classified as definite, probable and possible cases.
1) Definite cases were sputum culture positive for M. Tuberculosis
with compatible clinical or radiological features (as assessed by
one or both readers), or additional microbiological confirma-
tion (any grade of smear or further positive culture).
2) Probable cases were those with one culture positive for M.
tuberculosis without compatible clinical or radiological features
or smear positive grade 1+ or more, with or without
compatible clinical or radiological features (as assessed by
one or both readers).
3) Possible cases were culture-negative with either classical
radiological features (pleural effusion, cavitation, or upper
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lobe changes, requiring two readers’ consensus) or one or more
scanty positive smear.
Compatible radiological features were any feature suggestive of
tuberculosis on chest radiography. Compatible clinical features
consisted of at least one of cough .2weeks, night sweats,
unintentional weight loss or temperature $38oC. All results (from
enrolment and/or follow-up) could contribute to tuberculosis case
definitions. Undiagnosed tuberculosis was defined as definite or
probable tuberculosis in a person not taking treatment at
enrolment.
An ex-smoker was defined as having smoked at least 100
cigarettes, but was not smoking at study enrolment. A current
smoker was defined as having smoked at least 100 cigarettes and
was smoking at study enrolment.
Statistical Analysis
The target sample size was 1000 participants (new recruits and
currently incarcerated combined), aiming to determine a tuber-
culosis prevalence of 2% with precision of 0.9% assuming a 95%
confidence interval (CI). Data were analysed using Stata 11.0
(Stata Corporation, Texas, USA). Using logistic regression,
unadjusted and adjusted odds ratios (OR) were calculated, with
p-values from the likelihood ratio test. Continuous variables were
categorised for analysis. Age was categorised into three levels (20–
29 years, 30–34 years and .35years) and all others were
dichotomised around the median. Factors associated with undi-
agnosed tuberculosis in univariable analysis with p,0.2 were
considered for inclusion in a multivariable model. From the
shortlist of variables considered for inclusion, only those most
strongly associated with undiagnosed tuberculosis were included.
When variables were strongly associated with each other (e.g.
alcohol and smoking), only the variable more strongly associated
with the outcome was included. As previous tuberculosis treatment
was likely to be on the causal pathway between HIV infection and
undiagnosed tuberculosis, it was not considered for the multivar-
iable model. Sensitivities, specificities, negative and positive
predictive values for combinations of screening methods were
calculated. Only study screening tests performed at enrolment
were used to evaluate screening methods.
Results
Figure 1 summarises study inclusions, losses to follow-up, and
tuberculosis outcomes. A total of 1046 prisoners were offered
consent to the study, with 981/1046 (93.8%) consenting. Of those
consented 526 (53.6%) were currently incarcerated with a median
incarceration time of 73 months and 455 (46.4%) were newly
sentenced with a median duration of awaiting trial of 15 months.
The baseline characteristics of the participants were similar in the
two groups (table 1). The majority (914/981[93.2%]) were Black
African, the median age was 32 (interquartile range [IQR] 27–37)
years and the median number of prisoners per cell was 44 (IQR
41–55). Previous HIV testing was reported by 580/981 (59.1%)
and previous tuberculosis treatment by 126/981 (12.8%). Previous
tuberculosis treatment was reported more frequently by those
currently incarcerated than those newly sentenced (87/526
[16.5%] and 39/455 [8.6%], respectively; p,0.001).
Prevalence of Tuberculosis
At enrolment 10/981 (1.0%) participants were on anti-
tuberculous treatment. Three participants did not have enrolment
sputum cultures performed and were excluded from further
analyses. Of the remaining 968, 374 (38.6%) had at least one
clinical feature compatible with tuberculosis, and 337 (34.8%) had
a positive WHO symptom screen for people with HIV [25]. Using
the study definition, 446/968 (46.1%) were identified as tubercu-
losis suspects, among whom 332/446 (74.4%) had a one-month
follow up visit with repeat investigations.
The case definitions of definite and probable tuberculosis were
fulfilled by 28/968 (2.9%) and 6/968 (0.6%) participants
respectively, giving a prevalence of undiagnosed tuberculosis of
3.5% ([34/968]; 95% CI 2.4–4.9%). All 6/6 (100%) probable
tuberculosis cases were culture positive for M. tuberculosis. A further
39/968 (4.0%) fulfilled the case definition of possible tuberculosis,
which, if included, would give a prevalence of 7.5% ([73/968];
95% CI 6.0–9.4%).
The prevalence of undiagnosed tuberculosis (excluding possible
cases) was similar in the currently incarcerated and newly
sentenced groups (19/491 [3.9%] and 15/438 [3.4%], respective-
ly; p = 0.73). Among participants with undiagnosed tuberculosis,
5/34 (14.7%) were smear positive (any grade). Two participants
had 1+ positive smears (one had a single positive smear and the
other, two positive smears), two had 2+ positive smears (one had a
single positive smear and the other, one 2+ positive smear, and,
one 1+ positive smear) and one had a single scanty positive smear.
Among isolates from sputum culture, 1/34 (2.9%) had isoniazid
monoresistance and 1/34 (2.9%) had resistance to isoniazid and
rifampicin.
Prevalence of HIV
Urine HIV test results were available for 957/981 (97.6%)
participants, with 242 testing positive, giving a prevalence of HIV
infection of 25.3% (95% CI 22.6–28.2%). The prevalence was
similar in the currently incarcerated and newly sentenced groups
(132/519 [25.4%] and 110/438 [25.1%], respectively; p = 0.94).
The prevalence of HIV infection among those with undiagnosed
tuberculosis was 15/34 (44.1%).
Demographic and Clinical Risk Factors for Undiagnosed
Tuberculosis
The risk factor analysis for undiagnosed tuberculosis was
restricted to 929/981 (94.7%) participants, excluding 10 on
tuberculosis treatment at enrolment, 39 defined as ‘‘possible’’
tuberculosis and three without sputum cultures at enrolment.
Urine HIV results were available for 906/929 (97.5%). In the
univariable analysis (table 2) undiagnosed tuberculosis was more
common in those who had no prior incarceration, shared a cell
with .50 prisoners, drank alcohol, were ex-smokers, had HIV
infection and reported previous tuberculosis treatment.
Due to the small number of outcomes (n = 34), the multivariable
model was restricted to number of prisoners per cell, smoking
history and HIV status, which were most strongly associated with
undiagnosed tuberculosis in the univariable analysis. In the
adjusted analysis (for n= 878 participants with complete data,
table 2) being an ex-smoker (adjusted OR 2.6, 95% CI 1.2–5.9)
and HIV infection (adjusted OR 2.0, 95% CI 1.0–4.2) remained
associated with undiagnosed tuberculosis.
Sensitivity, Specificity and Predictive Values of Screening
Tools for Undiagnosed Tuberculosis
Using definite and probable tuberculosis as our gold standard,
the performance of different screening modalities was evaluated
for 867/981 (88.4%) participants who had complete data for all
symptoms and investigations (table 3).
The sensitivity of individual symptoms (cough of any duration;
cough .2 weeks; night sweats; fever or unintentional weight loss)
TB Screening in a South African Prison
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was low, ranging from 5.9% for night sweats to 35.3% for cough of
any duration (table 3). Specificity ranged from 79.6% for cough of
any duration to 91.8% for cough .2weeks. Sputum smear had
poor sensitivity (14.7%). The sensitivity and specificity of chest
radiographic features suggestive of tuberculosis was 70.6% and
92.2% respectively. While any chest radiographic abnormality had
a higher sensitivity (73.5%), specificity was lower (85.5%). A high
proportion of abnormal chest radiographs (11.0%) in this
population had evidence of trauma/bullets.
Combining symptoms (either any of cough .2weeks, night
sweats or unintentional weight loss [henceforth known as the
symptom combination]; or the WHO symptom screen for people
with HIV [25]) increased the sensitivity (29.4% and 38.2%
respectively), but at the cost of specificity (74.0% and 65.8%
respectively). A screening tool combining one or more symptoms
with chest radiographic features suggestive of tuberculosis
increased the sensitivity to .73% (table 3). The most sensitive
combinations (with a sensitivity of 79.4%), were adding chest
radiographic features suggestive of tuberculosis to cough of any
duration or the WHO symptom screen; however, again, specificity
was reduced (73.8% versus 61.3% respectively). All combinations
of symptoms and sputum smear (data not shown) had poor
sensitivity (,42%).
The performance of screening tools was assessed according to
HIV status for 846/867 (97.6%) participants who had HIV test
results (see Table 4). When stratified by HIV status, the
combination of cough of any duration and/or chest radiographic
features suggestive of tuberculosis still gave the highest sensitivity
and specificity in both HIV-negative and HIV-positive partici-
pants (sensitivity 84.2% versus 73.3% respectively and specificity
75.4% versus 70.2% respectively).
Discussion
As far as the authors are aware, this study is the first to
systematically evaluate, using a symptom screen, chest radiogra-
Figure 1. Study inclusions, losses to follow-up and tuberculosis outcomes. TB = Tuberculosis.
doi:10.1371/journal.pone.0087262.g001
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phy and sputum microscopy and culture, the prevalence of active
pulmonary tuberculosis, and, HIV in a representative sample of
male prisoners in Sub-Saharan Africa. The prevalence of
undiagnosed culture-positive tuberculosis was high at 3.5%, but
would rise to 7.5% if those with typical chest radiographs or scanty
sputum smears, but negative cultures, were included.
Direct comparison with other prison prevalence surveys from
Sub-Saharan Africa, which report tuberculosis prevalences rang-
ing from 1 to 6% [2,4,6–12] (3% at a prison in KwaZulu-Natal
South Africa [16]), is difficult, because of differing sampling
strategies, screening methodologies and case definitions. The
prevalence of tuberculosis found in our study is higher than the
estimated prevalence for the general population (0.8% in 2010
[14]), and, the mines (approximately 2.2% in 2010 [30]), in South
Africa. Results consistently show a higher prevalence of undiag-
nosed tuberculosis in prisons compared to the general population,
calling for urgent measures to address this. Untreated tuberculosis
among prisoners is not only a risk to other prisoners; it also has
wider implications for the general population through transmission
to prison staff, visitors, and communities after release [1].
Only 14.7% of prisoners with undiagnosed tuberculosis were
smear positive. Forty five percent of all notified pulmonary
tuberculosis cases in South Africa in 2010 were smear positive
(WHO 2011). This is in keeping with studies that show a lower
proportion of cases identified through active case finding are
smear positive, when compared with those identified through
passive case finding [31–33].
Identifying prisoners with active tuberculosis through screening,
and, commencing appropriate treatment, will make infectious
patients non-infectious. This should be coupled with encouraging
self-referral and infection control strategies such as isolating
infectious tuberculosis cases [1,2,21].
If high risk groups were identifiable, screening for tuberculosis
could be targeted. Factors independently associated with undiag-
nosed tuberculosis were being an ex-smoker and HIV infection.
Previous tuberculosis was strongly associated with undiagnosed
tuberculosis in the univariable analysis. The association with
previous tuberculosis has been reported in prison studies from
Cameroon [4], Bangladesh [34] and Brazil [26]. However, only
29% of prisoners with undiagnosed tuberculosis had previous
tuberculosis in our study. Studies from prison settings have not
previously demonstrated an association between tuberculosis and
being an ex-smoker. However, given that this is a cross-sectional
study, reverse causality cannot be excluded. While the association
between tuberculosis and HIV infection is well known, it has not
been widely reported on in prison studies mainly due the lack of
systematic screening for HIV infection. In a study among prisoners
in Cameroon [4], HIV infection was associated with prevalent
tuberculosis (including those on treatment) but not with undiag-
nosed prevalent tuberculosis. HIV infection is less strongly
Table 1. Characteristics of participants.
Characteristics*
All participants
(n=981){
Incarcerated $6
months(n =526)`
Newly sentenced
(n=455)1
Age (years) Median (IQR) 32 (27–37) 34 (30–39) 29 (26–35)
Country of origin South Africa 862 (87.9) 478 (90.9) 384 (84.4)
Ethnic group Black African 914 (93.2) 491 (93.3) 423 (93.0)
No. of years in school Median (IQR) 10 (9–12) 10 (9–12) 10 (8–12)
Duration of incarceration (months) Median IQR) 34 (16–79) 73 (43–102) 15 (6–26)II
Previous incarceration Yes 409 (41.7) 232 (44.1) 177 (38.9)
No. of prisoners per cell(n = 951) Median (IQR) 44 (41–55) 44 (41–45) 54 (40–76)
History of mine work Yes 34 (3.5) 18 (3.4) 16 (3.5)
Health care worker Yes 42 (4.3) 19 (3.6) 23 (5.0)
Previous IVDU Yes 14 (1.4) 10 (1.9) 4 (0.9)
Ever drunk alcohol Yes 729 (74.3) 378 (71.9) 351 (77.1)
Smoking history Ex-smoker 190 (19.4) 140 (26.6) 50 (11.0)
Current smoker 568 (57.9) 254 (48.3) 314 (69.0)
Non-smoker 223 (22.7) 132 (25.1) 91 (20.0)
Self-reported previous HIV test Yes 580 (59.1) 361 (68.6) 219 (48.1)
Self-reported previous HIV test result(n = 578) Negative 391 (67.6) 239 (66.4) 152 (69.7)
Positive 168 (29.1) 115 (31.9) 53 (24.3)
Indeterminate 3 (0.5) 2 (0.6) 1 (0.5)
Don’t know 16 (2.8) 4 (1.1) 12 (5.5)
Maxim HIV-1 urine EIA(n = 957) Positive 242 (25.3) 132 (25.4) 110 (25.1)
Self reported current ART use(n = 168) Yes 88 (52.4) 60 (52.2) 28 (52.8)
Previous TB treatment Yes 126 (12.8) 87 (16.5) 39 (8.6)
*Data are number of participants (percent) unless otherwise indicated;
{denominator = 981unless otherwise indicated;
`denominator = 526 unless otherwise indicated;
1denominator = 455 unless otherwise indicated;
||Duration awaiting trial.
IQR = Interquartile range; IVDU= Intravenous drug use; ART =Antiretroviral therapy; TB = Tuberculosis; No =Number.
doi:10.1371/journal.pone.0087262.t001
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associated with prevalent compared with incident tuberculosis [35]
and may be a less important risk factor in prisons, where the risk
among HIV negative people is also high, compared with the
general population. Our results to a certain extent corroborate this
finding; the odds of HIV infection in those with undiagnosed
tuberculosis was relatively low. In addition, screening based on
HIV status would miss a large proportion of undiagnosed
tuberculosis patients; the prevalence of HIV infection in those
Table 2. Risk factors for undiagnosed tuberculosis*.
Risk factor/Category
Undiagnosed TB
N=34/929{`
Unadjusted OR
(95% CI) P-value
Adjusted OR1
(95% CI) P-value
Prevalence %
Participant type
Incarcerated $6 months 19/491 3.9 1.0
Newly sentenced 15/438 3.4 0.9 (0.4–1.8) 0.72
Age (years)
20–29 13/351 3.7 1.0 0.98
30–34 9/237 3.8 1.0 (0.4–2.4)
.35 12/341 3.5 0.9 (0.4–2.1)
Duration of incarceration (years)
.3 14/438 3.2 1.0 0.48
#3 20/491 4.1 1.3 (0.6–2.6)
Previous incarceration
No 24/543 4.4 1.0 0.14
Yes 10/386 2.6 0.6 (0.3–1.2)
Number of prisoners per cell N=33/901
#50 19/631 3.0 1.0 0.12 1.0
.50 14/270 5.2 1.8 (0.9–3.6) 1.8 (0.9–3.6) 0.12
History of mine work
No 34/896 3.8 0.63**
Yes 0/33 0.0
Health care worker
No 33/888 3.7 1.0 0.74
Yes 1/41 2.4 0.6 (0.0–4.1)
Intravenous drug use#
No 34/918 3.7 .0.99**
Yes 0/11 0.0
Ever drunk alcohol
No 5/236 2.1 1 0.12
Yes 29/693 4.2 2.0 (0.8–5.3)
Smoking History
Current smoker 14/547 2.6 1.0 0.02 1.0
Ex-smoker 13/170 7.7 3.2 (1.5–6.8) 2.6 (1.2–5.9) 0.07
Non-smoker 7/212 3.3 1.3 (0.5–3.3) 1.3 (0.5–3.2)
Maxim HIV-1 Urine EIAN=34/906
Negative 19/682 2.8 1.0 0.01 1.0
Positive 15/224 6.7 2.5 (1.3–5.0) 2.0 (1.0–4.2) 0.06
Previous TB treatment
No 24/826 2.9 1.0 0.003
Yes 10/103 9.7 3.6 (1.7–7.7)
*Undiagnosed tuberculosis defined as participants fulfilling the case definition of definite or probable tuberculosis. {Numerator (undiagnosed tuberculosis cases) = 34
unless otherwise indicated. `Denominator = 929 unless otherwise indicated (10 participants on tuberculosis treatment at enrolment, 39 ‘‘possible’’ tuberculosis cases
and 3 participants without sputum cultures at enrolment were excluded). 1Adjusted for number of prisoners per cell, smoking history and HIV status; n = 878 for
adjusted model; numerator (undiagnosed tuberculosis) = 33 for adjusted model. **Fisher’s exact test. #3 participants reporting previous IVDU use excluded from the
analysis (1 without sputum culture at enrolment; 2 with possible tuberculosis).
TB = Tuberculosis; OR =Odds ratio; CI = Confidence interval.
doi:10.1371/journal.pone.0087262.t002
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with undiagnosed tuberculosis was 44.1% and in practice HIV
status of all prisoners would not be known. Therefore in this
setting, the risk of tuberculosis is not limited to conventional at risk
groups, necessitating universal screening.
Table 3. Performance of screening tools for undiagnosed tuberculosis* (N= 867).
Screening tools:
Prevalence n(%)
(N=867){
Sensitivity
(N=34)
Specificity
(N=833) PPV NPV
Cough .2 weeks 76/867 (8.8) 23.5 91.8 10.5 96.7
Any cough 182/867 (21.0) 35.3 79.6 6.6 96.8
Night sweats 112/867 (12.9) 5.9 86.8 1.8 95.8
Fever 89/867 (10.3) 14.7 89.9 5.6 96.3
Self-reported weight loss 132/867 (15.2) 17.7 84.9 4.6 96.2
Symptom combination` 227/867 (26.2) 29.4 74.0 4.4 96.2
WHO tool1 298/867 (34.4) 38.2 65.8 4.4 96.3
CXR features suggestive of TB 89/867 (10.3) 70.6 92.2 27.0 98.7
Any CXR abnormality# 146/867 (16.8) 73.5 85.5 17.1 98.8
Combination of screening tools:
Cough .2weeks or CXR features suggestive of TB 151/867 (17.4) 73.5 84.9 16.6 98.7
Any cough or CXR features suggestive of TB 245/867 (28.3) 79.4 73.8 11.0 98.9
Symptom combination` or CXR features suggestive of TB 286/867 (33.0) 73.5 68.7 8.7 98.4
WHO tool1 or CXR features suggestive of TB 349/867 (40.2) 79.4 61.3 7.7 98.7
Data are percentages unless otherwise indicated. *Undiagnosed tuberculosis defined as participants fulfilling the case definition of definite or probable tuberculosis. {
Denominator = 867 unless otherwise indicated (10 participants on tuberculosis treatment at enrolment, 39 ‘‘possible’’ tuberculosis cases, 3 participants without sputum
cultures at enrolment and 62 with missing chest radiographs at enrolment were excluded). #Any CXR abnormality = active tuberculosis 89 (61.0%); previous tuberculosis
23 (15.8%); trauma/bullets 16 (11.0%); abnormal cardiac silhouette 9 (6.2%); other 9 (6.2%). `Any of cough .2 weeks, night sweats or unintentional weight loss. 1Any of
current cough, fever, unintentional weight loss or night sweats (WHO symptom screen for people with HIV [25]). NPV = negative predictive value; PPV= positive
predictive value; WHO=World Health Organization; CXR =Chest radiograph; TB = tuberculosis.
doi:10.1371/journal.pone.0087262.t003
Table 4. Performance of screening tools for undiagnosed tuberculosis* stratified by HIV status (N = 846).
Screening tools:
Prevalence
(N=846){ Sensitivity (N=34)
Specificity
(N=812) PPV NPV
HIV-N
n=633
HIV-P
n=213
HIV-N
n=19
HIV-P
n=15
HIV-N
n=614
HIV-P
n=198 HIV-N HIV-P HIV-N HIV-P
Cough .2 weeks 7.6 12.7 21.0 26.7 92.8 88.4 8.3 14.8 97.4 94.1
Any cough 19.4 24.9 31.6 40.0 80.9 76.3 4.9 11.3 97.4 94.4
Night sweats 10.9 18.3 0.0 13.3 88.8 81.3 0.0 5.1 96.6 92.5
Fever 8.9 13.6 10.5 20.0 91.2 86.9 3.6 10.3 97.0 93.5
Reported weight loss 13.4 20.7 10.5 26.7 86.5 79.8 2.3 9.1 96.9 93.5
Symptom combination` 23.5 34.3 21.0 40.0 76.4 66.2 2.7 8.2 96.9 93.6
WHO tool1 31.1 43.7 31.6 46.7 68.9 56.6 3.0 7.5 97.0 93.3
CXR suggestive of TB 9.3 13.1 79.0 60.0 92.8 90.4 25.4 32.1 99.3 96.8
Any CXR abnormality 15.3 20.2 79.0 66.7 86.6 83.3 15.5 23.3 99.3 97.1
Combination of screening tools:
Cough .2 weeks or CXR suggestive of TB 15.5 23.5 79.0 66.7 86.5 79.8 15.3 20.0 99.2 96.9
Any cough or CXR suggestive of TB 26.4 32.9 84.2 73.3 75.4 70.2 9.6 15.7 99.4 97.2
Symptom combination` or
CXR suggestive of TB
30.2 41.3 79.0 66.7 71.3 60.6 7.9 11.4 99.1 96.0
WHO tool1 or CXR suggestive of TB 37.1 48.8 84.2 73.3 64.3 53.0 6.8 10.6 99.2 96.3
Data are percentages. * Undiagnosed tuberculosis defined as participants fulfilling the case definition of definite or probable tuberculosis. { Denominator = 846 unless
otherwise indicated (10 participants on tuberculosis treatment at enrolment, 39 ‘‘possible’’ tuberculosis cases, 3 participants without sputum cultures at enrolment,
62 with missing chest radiographs at enrolment and 21 with missing urine HIV test results were excluded). `Any of cough $2weeks, night sweats or unintentional
weight loss. 1Any of current cough, fever, weight loss or night sweats (WHO symptom screen for people with HIV [25]). NPV = negative predictive value; PPV= positive
predictive value; HIV-N =HIV-negative; HIV-P =HIV-positive; WHO=World Health Organization; CXR =Chest radiograph; TB = tuberculosis.
doi:10.1371/journal.pone.0087262.t004
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The proportion of participants with undiagnosed tuberculosis
was similar among newly sentenced and currently incarcerated
prisoners. Newly sentenced prisoners had spent a median duration
of 15 months awaiting trial prior to being sentenced. Therefore the
two groups studied were more homogenous in terms of duration of
incarceration than originally anticipated at the start of the study.
In most penal systems, people may remain in detention facilities
for long periods. In addition, on univariable analysis duration of
incarceration was not associated with undiagnosed tuberculosis.
Therefore, we recommend screening for all those entering the
prison system, and periodic rescreening of the incarcerated
population. Newly sentenced prisoners with an expected stay of
less than three months were excluded from the study. However,
the median duration that newly sentenced prisoners had awaited
trial reflects prolonged exposure to the penal system prior to being
sentenced. This justifies recommendations for screening all those
entering the prison system.
Our data suggests that chest radiography in combination with
cough of any duration should be used to screen new entrants to
prisons and the incarcerated population. Likewise, chest radiog-
raphy in combination with cough of any duration should be used
to screen both HIV positive and HIV negative prisoners. Due to
the small number of smear positive cases, we were unable to
investigate the role of screening tools in identifying smear positive
cases.
Our results support CDC [36] and WHO [21] guidance, which
recommends chest radiography in addition to standardised
symptom screening for all prisoners entering high tuberculosis
risk prisons. Data from Brazil [24,26] and Hong Kong [27] also
support the utility of chest radiography for screening in prisons.
The positive predictive value of the combination of chest
radiographic features suggestive of tuberculosis and cough of any
duration in our study was 11.0%; for approximately every 10
people investigated further, one will be found to have tuberculosis.
This is in line with recommendations for sputum microscopy [37].
Mass miniature radiography for new entrants has been imple-
mented in US detention centres at a cost of only $3 per prisoner
screened and found to increase case finding and speed up isolation
of tuberculosis cases [38,39]. However, the logistics of conducting
chest radiographic screening within prisons, including the staffing
and expertise required, maintenance of equipment and movement
of prisoners, also needs to be considered if implementation is
planned. Modelling studies in prisons support the effectiveness of
annual chest radiographic screening (with and without symptom
screening) in decreasing tuberculosis prevalence, and, its cost
effectiveness [40,41]. However, model settings and assumptions
may limit the generalisability of findings to high tuberculosis and
HIV burden settings, necessitating further work in this area.
The role of new diagnostic tests for tuberculosis, in particular
the role of the Xpert MTB/RIF, requires full assessment in this
population. With reported overall sensitivities ranging from 73.3%
to 97.6%, the Xpert MTB/RIF has been evaluated as both a
diagnostic and screening tool [42,43]. The rapid identification of
patients with drug resistant tuberculosis, with timely commence-
ment of treatment, would also help to prevent the spread of drug
resistant disease [43]. Following WHO endorsement, it is being
widely rolled out in South Africa, aiming to replace smear
microscopy [42,43]. Identifying whom to test with the Xpert
MTB/RIF, given the low sensitivity of symptoms, is still a
challenge. The cost per Xpert MTB/RIF test is greater than
smear microscopy. However, given the high specificity even in the
context of a prevalence survey [44], it could potentially be used as
a screening and diagnostic test simultaneously, which could have
overall cost-savings by limiting the number of investigations
needed per diagnosis, particularly given the recent decrease in
price of the Xpert MTB/RIF test. A screening study conducted
among HIV positive prisoners in Malaysia using a single sample of
unprocessed sputum found a sensitivity of 53% and a specificity of
100% [45]. Further work is required to investigate test character-
istics among all prison populations, including using different
screening algorithms. Modelling studies from prisons in the former
Soviet Union, community ART programmes in South Africa and
diagnostic services in India and Sub-Saharan Africa suggest that
screening and diagnosis of tuberculosis with the Xpert MTB/RIF
is cost-effective [40,46,47], although the limited generalisability of
findings to prisons in Sub-Saharan Africa warrants further work in
this area.
Anonymised HIV testing was undertaken to ensure high uptake
to testing, to enable tuberculosis results to be fully interpreted. The
prevalence of HIV infection among prisoners was high at 25%,
arguing for routine offer of HIV testing with linkage to care, as
well as active case finding for tuberculosis, tuberculosis infection
control measures and scale-up of isoniazid preventive therapy
usage [22,48]. However, the lower specificity of the HIV urine
EIA could have resulted in an overestimation of HIV prevalence,
which should be considered when interpreting results.
Strengths of our study include representative sampling and high
uptake into the study. Limitations include incomplete follow up of
tuberculosis suspects, which could have resulted in missed
tuberculosis diagnoses: thus the prevalence of undiagnosed
tuberculosis of 3.5% is a minimum estimate; indeed if cases
classified as ‘‘possible’’ (based on chest radiographic features highly
consistent with tuberculosis and scanty sputum smears) had been
included, the prevalence of undiagnosed tuberculosis could be as
high as 7.5%.
Conclusions
We found a high prevalence of undiagnosed tuberculosis in this
South African prison, justifying universal screening for new
entrants to the facility and periodic rescreening of those
incarcerated. Our data suggest a screening tool comprising cough
of any duration and chest radiography; further work is needed to
establish how best to use new tests for tuberculosis in screening and
diagnostic algorithms in this setting.
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